Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD Study of TT-00920 in Healthy Subjects
NCT04364789Phase 1Completed
- Sponsor
- TransThera Biosciences
- Start
- Feb 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TT-00920 in chronic heart failure (CHF) (7 arms), sponsored by TransThera Biosciences. Primary endpoints: Treatment Emergent Adverse Events at 10 days, Number of participants with Abnormal Laboratory Values at 10 days and 7 more. Started Feb 2020; status: completed.
02
Drugs
TT-00920
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT04364789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364789.